Your browser doesn't support javascript.
loading
High-Risk Features of Esophageal Adenocarcinoma Following Neoadjuvant Chemoradiation: Patients for Whom Surgery Should Not Be Delayed.
Bayley, Erin M; Ivy, Megan L; Shewale, Jitesh B; Ge, Phillip S; Antonoff, Mara B; Francis, Ashleigh M; Hofstetter, Wayne L; Mehran, Reza J; Rajaram, Ravi; Rice, David C; Roth, Jack A; Sepesi, Boris; Vaporciyan, Ara A; Walsh, Garrett L; Lee, J Jack; Louie, Brian E; Swisher, Stephen G.
Afiliação
  • Bayley EM; Department of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, TX.
  • Ivy ML; Division of Thoracic Surgery, Swedish Medical Center and Cancer Institute, Seattle, WA.
  • Shewale JB; Department of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, TX.
  • Ge PS; Department of Gastroenterology, Hepatology, and Nutrition, University of Texas MD Anderson Cancer Center, Houston, TX.
  • Antonoff MB; Department of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, TX.
  • Francis AM; Department of Plastic Surgery, University of Texas MD Anderson Cancer Center, Houston, TX.
  • Hofstetter WL; Department of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, TX.
  • Mehran RJ; Department of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, TX.
  • Rajaram R; Department of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, TX.
  • Rice DC; Department of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, TX.
  • Roth JA; Department of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, TX.
  • Sepesi B; Department of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, TX.
  • Vaporciyan AA; Department of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, TX.
  • Walsh GL; Department of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, TX.
  • Lee JJ; Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX.
  • Louie BE; Division of Thoracic Surgery, Swedish Medical Center and Cancer Institute, Seattle, WA.
  • Swisher SG; Department of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, TX.
Ann Surg ; 277(5): 721-726, 2023 05 01.
Article em En | MEDLINE | ID: mdl-36052678
ABSTRACT

OBJECTIVE:

Clinical predictors of pathological complete response have not reliably identified patients for whom an organ-sparing approach following neoadjuvant chemoradiation be undertaken for esophageal cancer patients. We sought to identify high-risk predictors of residual carcinoma that may preclude patients from a selective surgical approach.

BACKGROUND:

Patients treated with neoadjuvant chemoradiation followed by esophagectomy for esophageal adenocarcinoma were identified. PATIENTS AND

METHODS:

Correlation between clinical and pathologic complete responses were examined. Regression models and recursive partitioning were utilized to identify features associated with residual carcinoma. External validation of these high-risk factors was performed on a data set from an independent institution.

RESULTS:

A total of 326 patients were identified, in whom clinical complete response was noted in 104/326 (32%). Pathologic complete response was noted in only 33/104 (32%) of these clinical complete responders. Multivariable analysis identified that the presence of stricture ( P =0.011), positive biopsy ( P =0.010), and signet ring cell histology ( P =0.019) were associated with residual cancer. Recursive partitioning corroborated a 94% probability of residual disease, or greater, for each of these features. The positive predictive value was >90% for these characteristics. A SUV max >5.4 at the esophageal primary in the absence of esophagitis was also a high-risk factor for residual carcinoma. External validation confirmed these high-risk factors to be implicated in the finding of residual carcinoma.

CONCLUSIONS:

Clinical parameters of response are poor predictors of complete pathologic response leading to challenges in selecting candidates for active surveillance. However, we characterize several high-risk features for residual carcinoma which indicate that esophagectomy should not be delayed.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Esofágicas / Adenocarcinoma Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Esofágicas / Adenocarcinoma Idioma: En Ano de publicação: 2023 Tipo de documento: Article